Christine: The industry of healthcare has made huge strides over the years if you look at the innovation that has taken place.
Peter: You're seeing a massively accelerated pace of this technological development.
Lisa: I think that the word disruptive is a word that's synonymous with healthcare today.
Peter: It's a very exciting time, a very dynamic time, but one with a lot of disparate factors that are all at play.
Lisa: At J.P. Morgan we know the industries well, we know the trends, we know what institutional investors are going to be looking for.
Christine: J.P. Morgan has a long history in working with and advising healthcare companies within the life sciences industry.
Sam: These are people working in very complex areas of science, and they're about to make a scientific discovery that's going to impact millions and millions of people for positive reason.
Sam: One of the reasons we started the life sciences practice is we saw a need in the sector, in the community, in the market for this type of advice.
Peter: We focus on the things that we're really good at, so our clients can focus on the things that they're really good at. What they really want is a partner that understands what they do. This is really the only effort that I know of to dedicate a full banking effort around what does the company do? How do I manage my own personal wealth? How do I expand overseas? Start thinking about an exit down the road. All of those different aspects, we can help with.
Christine: Being able to work with a client and their company across their entire lifecycle, from start to finish, is really one of the biggest key strengths that we see for entrepreneurs and for companies.
Lisa: What makes J.P. Morgan different is that we work really collaboratively, and every day it's about building each other up and being a single J.P. Morgan to our clients across the entire bank.
Christine: When a client has that ultimate success, whether it's FDA approval, the sale of their company, or an IPO, being able to share in the success and know that we gave them the sleep at night is one of the greatest points of satisfaction in our role.
Peter: One of the challenges we see in the market right now is entrepreneurs will come to us and say, "I'm not ready for J.P. Morgan yet. We're too small." You might be small in size, which a lot of life sciences companies are, but it doesn't mean you're small in potential. There's many different aspects to the life sciences community where your first reaction is how do I help this company? Being able to help companies along this journey to do something that's truly life changing, I think it's one of the things that drives our people that are focused on this space to go above and beyond.
